Lucid Diagnostics Inc (LUCD NASDAQ) stock market data APIs
$0.6251
-0.03(-4.8%)
as of October 7, 2026
Try our APIs with
free plan!
Lucid Diagnostics Inc Financial Data Overview
Price chart is built with
Anychart
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.
Prev. Close
0.6251
Open
0.5941
High
0.6594
Low
0.5919
52 wk Range
0.5-1.6293
Market Cap
115 M
Shares Outstanding
191 M
Revenue
5 445 K
EPS
-0.08
Beta
1.124
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Lucid Diagnostics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Lucid Diagnostics Inc data using free add-ons & libraries
Get Lucid Diagnostics Inc Fundamental Data
Lucid Diagnostics Inc Fundamental data includes:
- Net Revenue: 5 445 K
- EBITDA: -49 808 000
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-13
- EPS/Forecast: -0.05
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Lucid Diagnostics Inc News
New
PAVmed Inc. Q2 2026 Earnings Call Summary
PAVmed Inc. Q2 2026 Earnings Call Summary - Moby Strategic Execution and Portfolio Optimization Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest ...
Lucid Diagnostics Inc. Q2 2026 Earnings Call Summary
Lucid Diagnostics Inc. Q2 2026 Earnings Call Summary - Moby Strategic Execution and Market Access Progress Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how ...
Lucid Diagnostics Non-GAAP EPS of -$0.06 misses by $0.01, revenue of $1.47M misses by $0.46M
* Lucid Diagnostics press release [https://seekingalpha.com/pr/20618076-lucid-diagnostics-provides-business-update-and-reports-second-quarter-2026-financial-results] (LUCD [https://seekingalpha.com/...
Alphatec (ATEC) Q2 Earnings Lag Estimates
Alphatec (ATEC) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.02 per share a year ago. These figures are...
Get Lucid Diagnostics Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.